About Emmanuel Antonarakis
- Understanding resistance to new treatments for advanced, metastatic prostate cancer represents an unmet medical need.
- Dr. Antonarakis is studying genetic variants of the target of these new medicines as one possible mechanism for resistance.
- Understanding the genetic basis for resistance to Zytiga and Xtandi can lead to improved use of these treatments and should reveal new targets for treating these highly drug-resistant patients.
What this means to patients: Understanding mechanisms of resistance to Xtandi and Zytiga should lead to improved therapy for treatment-resistant patients with advanced, metastatic prostate cancer.
2013 Steve Wynn-PCF Young Investigator
Emmanuel Antonarakis, MD
Johns Hopkins University School of Medicine
Michael Carducci, MD and Jun Luo, PhD
Understanding mechanisms of response and resistance to abiraterone (Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer, by interrogation of tumor biopsies for androgen receptor splice variants.